Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

Novartis Investigative Site, Vienna

Novartis Investigative Site, Budapest

Novartis Investigative Site, Budapest

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Box Hill

Novartis Investigative Site, Basel

Novartis Investigative Site, Berlin

Novartis Investigative Site, Berlin

Novartis Investigative Site, Rüdersdorf

Novartis Investigative Site, Neuruppin

Novartis Investigative Site, Milan

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Itzehoe

Novartis Investigative Site, Madrid

Novartis Investigative Site, Málaga

Novartis Investigative Site, Celle

Novartis Investigative Site, Bielefeld

Novartis Investigative Site, Seville

Novartis Investigative Site, Bochum

Novartis Investigative Site, Krefeld

Novartis Investigative Site, Münster

Novartis Investigative Site, Siegen

Novartis Investigative Site, Erbach im Odenwald

Novartis Investigative Site, Ostfildern

Novartis Investigative Site, Kandel

Novartis Investigative Site, Ashkelon

Novartis Investigative Site, Neuburg am Inn

Novartis Investigative Site, Ulm

Novartis Investigative Site, Cefalù

Novartis Investigative Site, Jerusalem

Novartis Investigative Site, Bad Mergentheim

Novartis Investigative Site, Erfurt

Novartis Investigative Site, Prague

Novartis Investigative Site, Prague

Novartis Investigative Site, Teplice

Novartis Investigative Site, Helsinki

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Athens

Novartis Investigative Site, Ioannina

Novartis Investigative Site, Thessaloniki

Novartis Investigative Site, Athens

Novartis Investigative Site, Athens

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Barcelona